Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey I Shapiro

Showing results (1-10 of 277) with videos related to

Pageof 28
Sort By:
Cancer Cell|December 13, 2017
Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive SearchGeoffrey I Shapiro
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridolGeoffrey I Shapiro
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2006
Cyclin-dependent kinase pathways as targets for cancer treatmentGeoffrey I Shapiro
Expert Opinion on Therapeutic Targets|October 12, 2010
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumorsNeil Johnson, Geoffrey I Shapiro
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
Heat shock protein 90 inhibition in lung cancerTakeshi Shimamura, Geoffrey I Shapiro
Current Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinasesScott J Rodig, Geoffrey I Shapiro
Cancer Treatment and Research|November 17, 2023
Combining PARP Inhibition and Immunotherapy in BRCA-Associated CancersGeoffrey I Shapiro, Suzanne M Barry
Current Oncology Reports|April 29, 2010
Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancerJames M Cleary, Geoffrey I Shapiro
Cancer Research|March 26, 2002
Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phaseChristian B Matranga, Geoffrey I Shapiro
Cancer Discovery|December 15, 2015
Targeting CDK4 and CDK6: From Discovery to TherapyCharles J Sherr, David Beach, Geoffrey I Shapiro
Pageof 28

Showing results (1-10 of 277) with videos related to

Sort By:
Pageof 28
Cancer Cell|December 13, 2017
Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive SearchGeoffrey I Shapiro
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridolGeoffrey I Shapiro
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2006
Cyclin-dependent kinase pathways as targets for cancer treatmentGeoffrey I Shapiro
Expert Opinion on Therapeutic Targets|October 12, 2010
Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumorsNeil Johnson, Geoffrey I Shapiro
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 27, 2008
Heat shock protein 90 inhibition in lung cancerTakeshi Shimamura, Geoffrey I Shapiro
Current Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinasesScott J Rodig, Geoffrey I Shapiro
Cancer Treatment and Research|November 17, 2023
Combining PARP Inhibition and Immunotherapy in BRCA-Associated CancersGeoffrey I Shapiro, Suzanne M Barry
Current Oncology Reports|April 29, 2010
Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancerJames M Cleary, Geoffrey I Shapiro
Cancer Research|March 26, 2002
Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phaseChristian B Matranga, Geoffrey I Shapiro
Cancer Discovery|December 15, 2015
Targeting CDK4 and CDK6: From Discovery to TherapyCharles J Sherr, David Beach, Geoffrey I Shapiro
Pageof 28